CLINICAL TRIALS PROFILE FOR NERATINIB MALEATE
✉ Email this page to a colleague
All Clinical Trials for NERATINIB MALEATE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT05372614 ↗ | Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene | Not yet recruiting | National Cancer Institute (NCI) | Phase 1 | 2022-06-20 | This phase I trial tests the safety, side effects, and best dose of neratinib in combination with trastuzumab deruxtecan in treating patients with solid tumors that have spread to other parts of the body (metastatic) or that cannot be removed by surgery (unresectable), and have changes in a gene called human epidermal growth factor receptor 2 (HER2). Neratinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals tumor cells to multiply. This helps slow or stop the spread of tumor cells. Trastuzumab deruxtecan is in a class of medications called antibody-drug conjugates. It is composed of a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called deruxtecan. Trastuzumab attaches to HER2 positive tumor cells in a targeted way and delivers deruxtecan to kill them. Adding neratinib to trastuzumab deruxtecan may be able to shrink cancer with a change in the HER2 gene. |
| NCT06083662 ↗ | Neratinib and Trastuzumab Biosimilar in Patients With HER2 Mutated Advanced Solid Cancers | Active, not recruiting | Korean Cancer Study Group | Phase 2 | 2021-06-15 | Prospective, Basket, Open-label, Multi-dose, Single-arm, Simon's two-stage, Multi-center trial Study drug : neratinib + herzuma (trastuzumab biosimilar) |
| NCT06083662 ↗ | Neratinib and Trastuzumab Biosimilar in Patients With HER2 Mutated Advanced Solid Cancers | Active, not recruiting | Korea University Guro Hospital | Phase 2 | 2021-06-15 | Prospective, Basket, Open-label, Multi-dose, Single-arm, Simon's two-stage, Multi-center trial Study drug : neratinib + herzuma (trastuzumab biosimilar) |
| NCT06126276 ↗ | Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial) | Recruiting | National Cancer Institute (NCI) | Phase 2 | 2024-05-07 | This phase II ComboMATCH treatment trial compares the effect of neratinib to the combination of neratinib and palbociclib in treating patients with HER2 positive solid tumors. Neratinib and palbociclib are in a class of medications called kinase inhibitors. They work by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of tumor cells. Giving neratinib and palbociclib in combination may shrink or stabilize cancers that over-express a specific biomarker called HER2. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for NERATINIB MALEATE
Condition Name
| Condition Name for NERATINIB MALEATE | |
| Intervention | Trials |
| Metastatic Cancer | 1 |
| Metastatic Malignant Solid Neoplasm | 1 |
| Recurrent Malignant Female Reproductive System Neoplasm | 1 |
| Recurrent Malignant Solid Neoplasm | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for NERATINIB MALEATE
Trials by Country
Clinical Trial Progress for NERATINIB MALEATE
Clinical Trial Phase
Clinical Trial Sponsors for NERATINIB MALEATE
Sponsor Name
